Journal
Cancer Medicine
Publication Date
5-1-2023
Volume
12
Issue
9
First Page
10612
Last Page
10624
Document Type
Open Access Publication
DOI
10.1002/cam4.5799
Rights and Permissions
Mesa, RA, Hudgens, S, Floden, L, et al. Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies. Cancer Med. 2023; 12: 10612-10624. doi:10.1002/cam4.5799 © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Recommended Citation
Mesa, Ruben A; Oh, Stephen T; and et al., "Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies." Cancer Medicine. 12, 9. 10612 - 10624. (2023).
https://digitalcommons.wustl.edu/oa_4/2756
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
